# Comparative Bioavailability Study of UDCA

> **NCT02385032** · PHASE1 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ursodiol
- **DRUG:** URSO Forte

## Key facts

- **NCT ID:** NCT02385032
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-03
- **Final completion:** 2015-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2015-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02385032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02385032, "Comparative Bioavailability Study of UDCA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02385032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*